CAR-T for autoimmune disease Market Outlook 2026–2036: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief
What This Brief Covers
This Meticulous Next™ brief examines CAR-T cell therapy for autoimmune disease, in which engineered T cells remove the B cells that drive diseases such as lupus, myasthenia gravis and stiff person syndrome. It tests how fast early data turn into filings and approvals, and which participants capture value among developers, large biopharma firms, treatment centres, payers and manufacturing suppliers.
Kyverna Therapeutics initiated a rolling Biologics License Application for its CAR-T miv-cel (KYV-101) in stiff person syndrome with its first quarter 2026 results, and in August 2026 stated that it was on track to complete the submission in the fourth quarter of 2026. In October 2026 it presented the full one-year registrational data set showing sustained clinical benefit at MS Toronto, and in September 2026 it reported positive one-year durability data in stiff person syndrome and generalized myasthenia gravis. The conclusion is that the first CAR-T filing for an autoimmune disease is under way, and durability beyond one year is the evidence that regulators and payers will weigh.
The programme extends beyond neurology. The FDA granted RMAT designation for non-active secondary progressive multiple sclerosis in August 2026, updated data in treatment-refractory rheumatoid arthritis were presented at EULAR in June 2026, and a commercial manufacturing and supply agreement with ElevateBio was announced in July 2026. The conclusion is that one product is being prepared for several diseases and for commercial supply.
Lupus remains a main target. About 40% of lupus patients may develop nephritis and about 60% of those are expected to fail standard treatment, according to the developer,. Cabaletta Bio and Cullinan Therapeutics compete in lupus. The conclusion is that the lupus opportunity is large and the evidence is still earlier than in stiff person syndrome.
The brief treats CAR-T for autoimmune disease as a high-impact category with a ten year horizon to 2036 and identifies which diseases scale first and what each means for developers, large biopharma firms and payers.
It is a focused 106-page decision brief for biopharma firms, payers and investors. It presents an indicative trajectory rather than a segmented market model. Its purpose is to identify which diseases scale first and who captures value.
| Parameter | Details |
|---|---|
| Forward horizon | 2026–2036 (10 years) |
| Emerging force | CAR-T for autoimmune disease: lupus and myasthenia gravis data spurring pivotal programmes |
| Technology readiness | First rolling BLA in stiff person syndrome expected to complete in the fourth quarter of 2026; myasthenia gravis, lupus and multiple sclerosis programmes in clinical trials; commercial supply agreement signed |
| Indicative market size & forecast | The CAR-T for autoimmune disease market, covering CAR-T and related cell therapies for autoimmune disease in development and early use, related licensing and collaboration revenue, and related manufacturing and services, is valued at USD 0.1–0.2 billion in 2026 and is projected to reach USD 2.89–5.79 billion by 2036, at a CAGR of 40% |
| Mainstream inflection | ~2032, when approvals in several autoimmune diseases and lower cost manufacturing support routine use in refractory patients |
| Signal strength | A rolling BLA, one-year registrational data and an RMAT designation within about six months |
| Primary beneficiaries | Developers with registrational data; large biopharma firms with partnered programmes; suppliers with scaled cell manufacturing |
| Brief length / format | 106 pages · PDF + executive summary deck · instant delivery |
Understanding the Technology
T cells collected from the patient are engineered to carry a chimeric antigen receptor that targets CD19 on B cells, expanded and infused after lymphodepletion.
The treatment removes the B cells that produce harmful antibodies, and the immune system rebuilds with new B cells, which gives the prospect of remission without continuing drugs.
Safety centres on cytokine release, neurotoxicity and infection risk, managed in specialist centres.
Uses are neurology, rheumatology and nephrology, including stiff person syndrome, myasthenia gravis, lupus, multiple sclerosis and rheumatoid arthritis.
The limits are cost and complexity of treatment, the durability of remission, competition from antibodies and T cell engagers and funding of developers. The decade turns on whether one infusion gives remission that lasts for years.
Market Outlook
The CAR-T for autoimmune disease market, covering CAR-T and related cell therapies for autoimmune disease in development and early use, related licensing and collaboration revenue, and related manufacturing and services, is valued at USD 0.1–0.2 billion in 2026 and is projected to reach USD 2.89–5.79 billion by 2036, at a CAGR of 40%.
The 2026 base rests on collaboration and licensing revenue, trial related manufacturing and a first commercial supply agreement. Growth then follows the first approvals, wider filings in myasthenia gravis, lupus and multiple sclerosis and falling cost per patient.
The forecast is sensitive to durability data, the FDA decision on the first filing and payer coverage.
Scenarios
The base case assumes the first approval arrives around 2027 and registrational data in lupus and myasthenia gravis support approvals by 2030, giving the inflection in 2032. An accelerated case assumes fast approvals and lower manufacturing cost, bringing the inflection to 2030 and lifting the 2036 value to the top of the range. A delayed case assumes durability concerns and slow payer coverage, holding growth at the bottom of the range.
Factors Behind Growth
Growth drivers
- Refractory disease with limited options.
- Chronic cost of lifelong immunosuppressive treatment.
- Early clinical data on remission and safety.
- Reuse of the platform across many diseases.
Enablers
- Large biopharma collaborations.
- Developer and manufacturer partnerships.
- Public research funding.
- Commercial manufacturing and supply agreements.
Restraints and barriers
- Cost and complexity of treatment.
- Competition from antibodies and T cell engagers.
- Safety, infection risk and lymphodepletion needs.
- Funding constraints at developers.
The Forces at Play
The direction of CAR-T for autoimmune disease is set by demand from neurology and rheumatology patients, regulation, new targets and in vivo methods, treatment centre and payer adoption, and manufacturing cost.
Adoption Outlook
How the shift is likely to unfold across three time horizons.
First approval decision and further registrational read-outs in neurology.
Approvals broaden to rheumatology and nephrology.
CAR-T for autoimmune disease moves to earlier lines and more diseases.
Latest Strategic Developments
| Date | Development | Type | Significance |
|---|---|---|---|
| May 2026 | Kyverna Therapeutics initiates a rolling BLA submission for miv-cel in stiff person syndrome | Regulation | First rolling BLA for a CAR-T in autoimmune disease |
| Jun 2026 | Updated miv-cel data in ACPA-positive, treatment-refractory rheumatoid arthritis are presented at EULAR | Clinical | Extends the programme to rheumatology |
| Jul 2026 | Kyverna Therapeutics signs a commercial manufacturing and supply agreement with ElevateBio for miv-cel | Manufacturing | Prepares commercial supply |
| Aug 2026 | Kyverna Therapeutics announces RMAT designation for non-active secondary progressive multiple sclerosis and states it is on track to complete the SPS filing in the fourth quarter | Regulation | Adds expedited development in a third disease group |
| Sep 2026 | Kyverna Therapeutics reports positive one-year durability data for miv-cel in stiff person syndrome and generalized myasthenia gravis | Clinical | Supports durability beyond one year |
| Oct 2026 | Kyverna Therapeutics presents the full one-year registrational data set in stiff person syndrome at MS Toronto | Clinical | Completes the data package for the first filing |
Key Players & Competitive Landscape
The key participants in CAR-T for autoimmune disease include Kyverna Therapeutics, Inc., Cabaletta Bio, Inc., Cullinan Therapeutics, Inc., Autolus Therapeutics plc, Cartesian Therapeutics, Inc., Bristol-Myers Squibb Company, Novartis AG, Gilead Sciences, Inc., AstraZeneca PLC, AbbVie Inc., Eli Lilly and Company, Johnson & Johnson, ElevateBio, LLC, the treatment centres, patient groups, payers and societies, and the regulators and standards bodies listed by archetype below.
The brief profiles representative participants in each archetype and assesses which are positioned to lead as CAR-T for autoimmune disease matures.
CAR-T developers such as Kyverna Therapeutics, Cabaletta Bio and Cullinan Therapeutics lead the clinical programmes, while large biopharma and cell therapy firms, cell manufacturing and tools suppliers, treatment centres, patient groups, payers and societies, regulators, and standards bodies shape how fast CAR-T reaches patients. Competitive intensity is moderate in 2026 because a few developers are in registrational trials and large firms are building positions, and it rises as approvals arrive and as off-the-shelf, in vivo and antibody competitors reach the same patients.
| Archetype | Representative players | Position in 2026 | Outlook to 2036 |
|---|---|---|---|
| CAR-T developers | Kyverna Therapeutics, Cabaletta Bio, Cullinan Therapeutics, Autolus Therapeutics, Cartesian Therapeutics, Allogene Therapeutics, Fate Therapeutics, CRISPR Therapeutics | CAR-T and related products for autoimmune disease | Develop and supply cell therapies |
| Large biopharma and cell therapy firms | Bristol-Myers Squibb, Novartis, Gilead Sciences, AstraZeneca, AbbVie, Eli Lilly, Johnson & Johnson, Roche, Takeda | Autologous, partnered and in vivo programmes | License, acquire and commercialize cell therapies |
| Cell manufacturing and tools suppliers | ElevateBio, Lonza, Miltenyi Biotec, Thermo Fisher Scientific, Danaher, Charles River Laboratories | Cell processing, media and contract manufacturing | Make and test cell products at scale |
| Treatment centres, patient groups, payers and societies | Mayo Clinic, Friedrich-Alexander University Erlangen-Nuremberg, National Institutes of Health, Myasthenia Gravis Foundation of America, Lupus Foundation of America, American College of Rheumatology, European Alliance of Associations for Rheumatology, American Academy of Neurology, American Society of Gene & Cell Therapy, Alliance for Regenerative Medicine, UnitedHealth Group, CVS Health, Elevance Health | Treatment, guidance and coverage | Treat patients, set practice and pay for care |
| Government agencies and regulators | U.S. Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, Pharmaceuticals and Medical Devices Agency, National Medical Products Administration, Centers for Medicare and Medicaid Services | Approval and coverage | Approve products and set coverage |
| Standards bodies | Foundation for the Accreditation of Cellular Therapy, International Council for Harmonisation, United States Pharmacopeia | Accreditation and quality standards | Set quality standards |
Where value migrates.
In 2026 value sits with developers in registrational trials, with large firms that partner or acquire, and with suppliers of cell manufacturing. By 2032 it moves toward companies with approved products in several autoimmune diseases, because payers cover treatments that give remission without continuing drugs. By 2036 it settles in integrated cell therapy and manufacturing platforms. Margins hold for products with durable remission and narrow for late followers.
Who Will Win — and Why
The archetypes best positioned to capture value as the shift matures.
Firms that show durable remission and safety in filed indications.
Firms that bring registrational capacity and commercial reach.
Firms that cut cost per patient as volume grows.
Regulatory Landscape
| Jurisdiction | Milestone | Indicative timing | Effect on adoption |
|---|---|---|---|
| FDA guidance for cell and gene therapy products | US guidance on development and manufacture of cell therapies | In force | Shapes trial design and quality expectations |
| EU rules for advanced therapy medicinal products | EU framework for approval of advanced therapies | In force | Sets the approval path in Europe |
| Clinical trial approvals in the United States and Europe | Regulatory clearance for first-in-human and early trials | In force | Allows early programmes to enter patients |
| Long term follow-up requirements | Requirements to follow treated patients for years | In force | Add cost and time to development |
| Regenerative medicine advanced therapy designation | US programme that speeds development of serious condition cell therapies | In force | Granted to a CAR-T for multiple sclerosis in August 2026 |
Investment Signals
The signals converge on the first filing for the field. A CAR-T for stiff person syndrome is completing a rolling BLA, one-year registrational and durability data were reported in September and October 2026, and an RMAT designation and a commercial supply agreement followed within about three months. Each signal supports growth, and approval and payer coverage are still to come.
Structural limits include cost and complexity of treatment, safety and infection risk, competition from antibodies and T cell engagers and funding constraints. The brief tracks the FDA decision on the first filing, registrational read-outs in myasthenia gravis and lupus, payer coverage and cost per patient.
Stiff person syndrome and myasthenia gravis, then lupus and multiple sclerosis, then other diseases are the expected order of development.
Questions This Brief Answers
Strategic Implications
- CAR-T developers: complete registrational trials and show durable remission beyond one year.
- Large biopharma firms: partner for registrational capacity and decide the balance between autologous, off-the-shelf and in vivo products.
- Payers, treatment centres and suppliers: prepare coverage models and treatment pathways and scale cell processing and testing.
- Policy makers: clarify evidence and follow-up requirements for CAR-T in non-cancer disease.
- Investors: treat the first FDA decision, registrational read-outs, payer coverage and cost per patient as the leading indicators.
"A single infusion that gives drug-free remission changes the economics of chronic disease. The first filing will show how regulators and payers value it."
Table of Contents
Access & Licensing
A focused foresight brief, priced to circulate. Every option is delivered instantly and backed by analyst support.
every brief